- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,521GBP
- Report
- August 2025
- 192 Pages
Global
From €3227EUR$3,545USD£2,780GBP
€3585EUR$3,939USD£3,089GBP
- Report
- January 2026
Global
From €4460EUR$4,900USD£3,843GBP
- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,521GBP
- Report
- November 2025
- 182 Pages
Global
From €4096EUR$4,500USD£3,529GBP
- Report
- November 2025
- 200 Pages
Global
From €7237EUR$7,950USD£6,235GBP
- Report
- July 2025
- 350 Pages
Global
From €4505EUR$4,949USD£3,881GBP
- Report
- November 2025
- 150 Pages
Global
From €4415EUR$4,850USD£3,804GBP
- Report
- February 2026
- 133 Pages
Global
From €3500EUR$4,119USD£3,121GBP
- Report
- July 2022
- 263 Pages
Global
From €1800EUR$2,118USD£1,605GBP
- Report
- November 2021
- 222 Pages
Global
From €2731EUR$3,000USD£2,353GBP
- Report
- July 2022
- 165 Pages
Global
From €5416EUR$5,950USD£4,667GBP
- Report
- March 2024
- 200 Pages
Global
From €3778EUR$4,150USD£3,255GBP
- Report
- July 2023
- 145 Pages
Global
From €2867EUR$3,150USD£2,471GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,941GBP
- Report
- October 2024
- 87 Pages
Spain
From €3186EUR$3,500USD£2,745GBP
- Report
- November 2023
- 90 Pages
France
From €3186EUR$3,500USD£2,745GBP
- Report
- November 2023
- 81 Pages
Germany
From €3186EUR$3,500USD£2,745GBP
- Report
- October 2023
- 81 Pages
Japan
From €3186EUR$3,500USD£2,745GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €2731EUR$3,000USD£2,353GBP

The B Cell Maturation Antigen (BCMA) market is a subset of the oncology drugs market. BCMA is a protein found on the surface of B cells, a type of white blood cell. BCMA is a promising target for cancer immunotherapy, as it is expressed on multiple myeloma cells and other B-cell malignancies. BCMA-targeted therapies are designed to stimulate the body's immune system to recognize and attack cancer cells.
BCMA-targeted therapies are being developed by a number of companies, including Amgen, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. These companies are researching and developing BCMA-targeted therapies for multiple myeloma and other B-cell malignancies. Additionally, several clinical trials are underway to evaluate the safety and efficacy of BCMA-targeted therapies. Show Less Read more